Expanding Targets Beyond EP300/CBP: Beyond EP300 and CBP, PCAF and GCN5 have emerged as context-dependent regulators in cancer, with inhibitors such as GSK4037 and L-Moses revealing their potential as therapeutic targets (273, 274). This evidence concerns the gene CREBBP and cancer.